Vaxcyte officer Elvia Cowan plans $186K stock sale

Elvia Cowan reported selling 19,000 shares on October 5, 2026, with an aggregate market value of $1,648,060.

Available on EDGAR 11/02/2026 - 04:07 PM EST Accepted by SEC EDGAR 11/02/2026 - 04:07 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Vaxcyte, Inc. officer Elvia Cowan plans to sell 3,000 shares of common stock, with an aggregate market value of $185,640 and an approximate sale date of November 2, 2026. UBS Financial Services, Inc. is listed as broker. Cowan's reported prior sales include 19,000 shares on October 5, 2026, with an aggregate market value of $1,648,060.

Key Figures

Shares in proposed sale: 3,000 shares Aggregate market value: $185,640 Shares outstanding: 148,805,278 shares +2 more

5 metrics

Shares in proposed sale 3,000 shares Proposed sale by Elvia Cowan

Aggregate market value $185,640 Proposed sale

Shares outstanding 148,805,278 shares Outstanding-share count listed with proposed sale

Prior shares sold 19,000 shares Elvia Cowan sale on October 5, 2026

Aggregate market value $1,648,060 Elvia Cowan's sale on October 5, 2026

Key Terms

Rule 144, Exercise of Stock Options, shares outstanding

3 terms

Rule 144 regulatory

"definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Exercise of Stock Options financial

"Nature of acquisition: Exercise of Stock Options"

shares outstanding financial

"number of shares or other units outstanding"

Shares outstanding are the total number of a company’s stock units held by all shareholders, including institutional investors and company insiders — think of them as the total number of slices of the company’s ownership pie. Investors use this number to calculate how much of the company each share represents, and it directly affects per-share measures like earnings per share, ownership percentage and valuation; when the slice count changes, an investor’s claim and the company’s per-share metrics change too.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCVX shares does Elvia Cowan plan to sell?

Elvia Cowan is listed as planning to sell 3,000 shares of Vaxcyte common stock, with an aggregate market value of $185,640; the approximate sale date is November 2, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001960048
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Vaxcyte, Inc.
SEC File Number	001-39323
Address of Issuer	825 INDUSTRIAL ROAD, STE. 300 SAN CARLOS CALIFORNIA 94070
Phone	650-837-0111
Name of Person for Whose Account the Securities are To Be Sold	Cowan Elvia
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	UBS Financial Services, Inc 11 Madison Ave 4th Floor New York NY 10010	3000	185640.00	148805278	11/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/02/2026	Exercise of Stock Options	Issuer			3000	11/02/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Elvia Cowan 825 INDUSTRIAL ROAD, STE. 300 San Carlos CA 94070	Common	10/05/2026	19000	1648060.00

144: Remarks and Signature

Remarks
Date of Notice	11/02/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/08/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ UBS Financial Services Inc, as attorney-in-fact for Elvia Cowan
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)